검색
TG Therapeutics Inc
TGTX관심 목록에 추가
54.860USD
-0.890-1.60%
종가 07-28 16:00（ET）시세는 15분 지연됩니다
8.40B시가총액
17.14P/E TTM
자세한 내용은 TG Therapeutics Inc 회사
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
TG Therapeutics Inc 정보
종목 코드 TGTX
회사 이름TG Therapeutics Inc
상장일Dec 14, 1995
CEOWeiss (Michael S)
직원 수338
유형Ordinary Share
회계 연도 종료Dec 14
주소3020 Carrington Mill Blvd., Suite 475
도시MORRISVILLE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호27560-5435
전화18775758489
웹사이트https://www.tgtherapeutics.com/
종목 코드 TGTX
상장일Dec 14, 1995
CEOWeiss (Michael S)
TG Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
Dr. Sagar Lonial
Dr. Sagar Lonial
Independent Director
Independent Director
94.06K
--
이름
이름/직위
직위
주식 보유
변동
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
9.78M
--
Mr. Sean A. Power
Mr. Sean A. Power
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
690.61K
--
Mr. Kenneth (Ken) Hoberman
Mr. Kenneth (Ken) Hoberman
Independent Director
Independent Director
279.65K
--
Dr. Yann Echelard
Dr. Yann Echelard
Independent Director
Independent Director
223.82K
--
Mr. Daniel Hume, J.D.
Mr. Daniel Hume, J.D.
Independent Director
Independent Director
192.75K
--
Mr. Laurence Neil (Larry) Charney, CPA
Mr. Laurence Neil (Larry) Charney, CPA
Lead Independent Director
Lead Independent Director
179.69K
--
자주 묻는 질문
TG Therapeutics Inc의 상위 5대 주주는 누구인가요?
TG Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Mr. Michael S. Weiss, J.D.
TG Therapeutics Inc(TGTX)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, TG Therapeutics Inc의 주식을 보유한 기관은 총 760곳이며, 이들이 보유한 주식의 총 가치는 약 122.50M로 전체 발행 주식의 80.02%를 차지합니다. 이는 2025Q4 대비 4398281.00 증가한 수치입니다.
TG Therapeutics Inc의 최대 수익원은 무엇인가요?
2026Q1 기준, TG Therapeutics Inc의 Total product revenue, net 부문이 가장 높은 매출을 기록했으며, 금액은 606.93M로 전체 매출의 98.48%를 차지했습니다.